List view / Grid view
21 July 2016 | By Wickham Laboratories
Wickham Laboratories is pleased to introduce the Monocyte Activation Test (MAT) as the latest addition to its portfolio of in vitro alternatives to in vivo testing methods...
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer...
21 July 2016 | By Niamh Louise Marriott, Digitial Content Producer
Almost $3 million in funding to support a Phase II trial of a new therapeutic approach, developed by Amylyx, for the treatment of ALS...
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
With the EU orhpan drug designations, Cell Medica can now obtain regulatory and financial incentives for developing and marketing CMD-003 as a cancer...
20 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.
20 July 2016 | By Victoria White, Digital Content Producer
Hookipa Biotech has announced the start of a first-in-human study to evaluate the safety and immunogenicity of HB-101 against human cytomegalovirus...
19 July 2016 | By Victoria White, Digital Content Producer
The Asia-Pacific (APAC) osteoporosis market is set to grow from $4.5 billion in 2015 to $7.7 billion in 2022, according to GBI Research...
19 July 2016 | By Niamh Louise Marriott
Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma...
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
19 July 2016 | By Victoria White, Digital Content Producer
The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma...
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
15 July 2016 | By National Institute for Health and Care Excellent (NICE)
NICE is advertising for five Non-Executive Directors to help NICE improve outcomes for people using the NHS, public health and social care services...
15 July 2016 | By Victoria White, Digital Content Producer
Celgene’s Revlimid (lenalidomide) has been approved by the EC for the treatment of adult patients with relapsed or refractory mantle cell lymphoma...
14 July 2016 | By Victoria White, Digital Content Producer
A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances...
14 July 2016 | By Victoria White, Digital Content Producer
The Arthritis Advisory Committee voted unanimously in support of biosimilar etanercept for all five indications of the reference product...
